What happened
Atlantic Council's in-depth research report applies a data-focused AI supply-chain framework (training data, models, weights, APIs, SDKs) to the health and biopharma sectors, maps the spectrum of data components used by organizations worldwide, details five real-world use cases ranging from cancer prediction to cross-border genetic sequencing, and surveys fourteen major regulatory regimes (AI-specific and non-AI-specific) that touch the health AI data supply chain. It concludes with three high-level government recommendations and argues that irresponsible data use in these sectors can undermine patient privacy, create cybersecurity and national-security risks, and harm marginalized populations, while consent-permissioned data can often deliver health innovation at far lower compute and energy cost than general-purpose LLMs. Published 2026-09-22.
Why it matters
For executives in health, pharma, and regulated-data industries, it clarifies the cross-border data-sovereignty, privacy, and national-security exposure embedded in AI supply chains — a growing compliance and geopolitical risk as governments restrict cross-border health data flows.
Action needed
Map your organization's health/biopharma AI data components against the report's supply-chain framework and review regulatory exposure across the 14 surveyed regimes before expanding cross-border AI deployments.